The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...

HOUSTON--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker ...

A compassionate-use study has generated promising results for the potential treatment of muscular dystrophies using mesenchymal stem cells (MSCs) derived from Wharton’s jelly (WJ), a substance found ...

Almost Heaven Saunas combines Finnish engineering with American craftsmanship for home use. Benefits of sauna use for athletes include muscle recovery, improved circulation, and stress reduction. The ...

Emma Ciafaloni, MD, FAAN, dives into the latest developments in gene therapy for muscular dystrophies, focusing on Duchenne muscular dystrophy, and discusses challenges, genetic causes, and the ...

Conceptual paper illustration of human hands and DNA in a lab. Senior Correspondent For genetic conditions like Duchenne muscular dystrophy, there is little doctors can do to slow or treat the ...

Muscle-related damage and deficiencies impact a patient’s quality of life, and treatments can be limited or non-existent. Some patients find relief in physical therapy or surgery, but such approaches ...

Muscle stem cells enable our muscle to build up and regenerate over a lifetime through exercise. But if certain muscle genes are mutated, the opposite occurs. In patients suffering from muscular ...

Bradley Williams, PhD, a budding physicist, began to feel his muscles weaken in 1981. In 2002, after years of progressive muscle wasting, he lost his ability to walk. Now, Williams needs help getting ...

A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular dystrophy, according to new research from the Smidt Heart Institute at ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Topline results from a phase 3 clinical trial showed an ...

The FDA's recent expanded approval of delandistrogene moxeparvovec (Elevidys) widened access to the gene therapy to include ambulatory and non-ambulatory Duchenne muscular dystrophy patients ages 4 ...